YM-359445

an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor with highly potent antitumor activity against established tumors; structure in first source

Also Known As:

(3Z)-3-(6-((4-methylpiperazin-1-yl)methyl)quinolin-2(1H)-ylidene)-2-oxoindoline-6-carbaldehyde-O-(1,3-thiazol-4-ylmethyl)oxime mono-L-tartrate

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Amino, Nobuaki: 1 article (03/2006)
2.	Hisamichi, Hiroyuki: 1 article (03/2006)
3.	Ideyama, Yukitaka: 1 article (03/2006)
4.	Kudoh, Masafumi: 1 article (03/2006)
5.	Kuromitsu, Sadao: 1 article (03/2006)
6.	Matsuhisa, Akira: 1 article (03/2006)
7.	Samizu, Kiyohiro: 1 article (03/2006)
8.	Shibasaki, Masayuki: 1 article (03/2006)
9.	Shirasuna, Kenna: 1 article (03/2006)
10.	Tajinda, Katsuinori: 1 article (03/2006)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2006 - "In mice bearing various established tumors, including paclitaxel-resistant tumors, once daily oral administration of YM-359445 at doses of 0.5 to 4 mg/kg not only inhibited tumor growth but also reduced its vasculature. " 03/01/2006 - "YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors." 03/01/2006 - "Moreover, in human lung cancer A549 xenografts, YM-359445 markedly regressed the tumors (73%) at a dose of 4 mg/kg, whereas gefitinib caused no regression even at 100 mg/kg. Our results show that YM-359445 is more potent than orally bioavailable VEGFR2 tyrosine kinase inhibitors, which leads to great expectations for clinical applicability." 03/01/2006 - "The antitumor activity of YM-359445 was also tested in nude mice bearing various established tumors and compared with other VEGFR2 tyrosine kinase inhibitors (ZD6474, CP-547632, CGP79787, SU11248, and AZD2171), a cytotoxic agent (paclitaxel), and an epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib). "
2.	Lung Neoplasms (Lung Cancer) 03/01/2006 - "Moreover, in human lung cancer A549 xenografts, YM-359445 markedly regressed the tumors (73%) at a dose of 4 mg/kg, whereas gefitinib caused no regression even at 100 mg/kg. Our results show that YM-359445 is more potent than orally bioavailable VEGFR2 tyrosine kinase inhibitors, which leads to great expectations for clinical applicability."

Related Drugs and Biologics

1.	ErbB Receptors (EGF Receptor)
2.	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)
3.	Paclitaxel (Taxol)
4.	Cytotoxins (Cytolysins)
5.	Tyrosine Kinase Inhibitors
6.	Sunitinib (Sutent)
7.	Gefitinib (Iressa)
8.	cediranib (AZD2171)
9.	3- (4- bromo- 2,6- difluorobenzyloxy)- 5- (3- (4- pyrrolidin- 1- ylbutyl)ureido)isothiazole- 4- carboxylic acid amide
10.	vandetanib (ZD6474)

Related Therapies and Procedures

1.	Oral Administration